Celgene Corporation : Celgene Announces Additional $2.5 Billion Share Repurchase Program
06/13/2012| 08:10am US/Eastern
Recommend:
Celgene Corporation (NASDAQ: CELG) today announced that during its June
meeting the Company's Board of Directors authorized the repurchase of up
to an additional $2.5 billion of the Company's common stock. This
open-ended program is effective immediately. Purchases may be made in
the open market or in privately negotiated transactions from time to
time, as determined by Celgene's management and in accordance with the
requirements of the Securities and Exchange Commission.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of novel therapies for the
treatment of cancer and inflammatory diseases through gene and protein
regulation. For more information, please visit the company's Web site at www.celgene.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
Exchange Commission.
Celgene Corporation
Jacqualyn A. Fouse, 908-673-9956
Executive
Vice President and Chief Financial Officer
or
Patrick E.
Flanigan III, 908-673-9969
Vice President, Investor Relations
© Business Wire 2012
Recommend :
